Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?

Kagenori ItoTakahiro KimuraHajime OnumaRyuji TabataTatsuya ShimomuraKenta MikiMasayuki TomitaShin Egawa

Published in: The Prostate (2018)

Earlier induction of docetaxel in nmCRPC patients may prolong OS. Further prospective studies in more patients will be required to confirm our findings.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
squamous cell carcinoma
small cell lung cancer
radiation therapy
locally advanced
patient reported